Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Underutilization of Osteoporosis Screening in Patients With Severe COPD and Long Term Corticosteroid Use.

Journal of primary care & community health·2026
Same author

Impact of Adherence to the Global Algorithm for Initial Crossing Strategy Selection in Chronic Total Occlusion Percutaneous Coronary Intervention.

The American journal of cardiology·2026
Same author

Renal Venous Hypertension and Kidney Dysfunction: Implications for Clinical Practice.

Cardiology in review·2026
Same author

HydroDynamic Recanalization for Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS-CTO Registry.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Sotatercept for pulmonary arterial hypertension on background therapy: a systematic review and meta-analysis of randomized controlled trials.

Proceedings (Baylor University. Medical Center)·2026
Same author

My Patient Has Episodic Dyspnea: Should I Order Spirometry With Bronchodilators?

Chest·2025

Related Experiment Video

Updated: May 27, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Hyperthyroidism and pulmonary hypertension: an important association.

Sailaja Vallabhajosula1, Saba Radhi, Cihan Cevik

  • 1Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, 79430, USA.

The American Journal of the Medical Sciences
|November 25, 2011
PubMed
Summary

Hyperthyroidism can cause pulmonary hypertension (PH). Treating thyroid disorders effectively lowers pulmonary artery pressures, suggesting PH screening for hyperthyroid patients is crucial.

More Related Videos

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

Related Experiment Videos

Last Updated: May 27, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

Area of Science:

  • Cardiology
  • Endocrinology
  • Pulmonology

Background:

  • Pulmonary hypertension (PH) is a complex condition with diverse causes.
  • World Health Organization Group 5 PH involves unclear mechanisms, including thyroid disorders.
  • The association between hyperthyroidism and PH requires further investigation.

Purpose of the Study:

  • To review the literature on the link between hyperthyroidism and pulmonary hypertension.
  • To analyze treatment outcomes for patients with both conditions.

Main Methods:

  • Literature review of 20 publications.
  • Analysis of data from 164 patients with hyperthyroidism and pulmonary hypertension.

Main Results:

  • Systolic pulmonary artery (PA) pressures ranged from 28 to 78 mm Hg.
  • Treatment for hyperthyroidism (medications, radioactive iodine, surgery) reduced mean PA systolic pressure from 39 mm Hg to 30 mm Hg.

Conclusions:

  • Pulmonary hypertension should be considered in hyperthyroid patients presenting with dyspnea.
  • Screening for hyperthyroidism in PH patients is recommended, as treatment can reduce PA pressures.
  • Further research is needed to understand the long-term outcomes and underlying mechanisms linking hyperthyroidism and PH.